Popular topics to explore
Gland Pharma to Acquire Its US Subsidiary
GLAND Gland Pharma Limited has approved the acquisition of 100% of the equity share capital of Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd., another wholly owned subsidiary of the company.
The transaction, approved by t…
Gland Pharma to Make US Arm Direct Wholly-Owned Subsidiary
Gland Pharma will acquire a 100% stake in Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd. for a cash consideration of $501,208, simplifying its corporate structure. Key Highlights • Gland Pharma will acquire 100% equity of…
Gland Pharma Pays ₹1.40 Lakh Penalty Imposed
GLAND has paid a combined penalty of ₹1.40 lakh to NSE and BSE in connection with a technical compliance breach under SEBI LODR regulations concerning the appointment of an independent director aged over 75 years. The company settled the f…
6th Sep · SEBI Registration INH000016649
SEBI Registration INH000016649 · 6th Sep
Gland Pharma Holds Near Highs Despite Fosun Stake Sale
Gland Pharma gained 0.84% on September 4 despite a major Fosun stake sale, with the stock trading close to its 52-week high.
Gland Pharma Ltd. (NSE: GLAND ) remained resilient on September 4, 2026, closing 0.84% higher despite significant…
Fosun Pharma Offloads 4.5% Stake in Gland Pharma
Chinese pharmaceutical major Fosun Pharma has sold a 4.5–4.55% stake in Hyderabad-based !GLAND Pharma for ₹2,121.5 crore through block deals on September 4, 2026. Fosun Pharma Industrial Pte Ltd, a wholly owned subsidiary of Shanghai Fosun…
Cohance Lifesciences Receives 4 FDA Form 483 Observations
COHANCE Lifesciences received four FDA Form 483 observations following a plant inspection. This is worth reading directly alongside the Gland Pharma inspection we covered recently, that facility received zero observations from the FDA. He…
₹2,121 Crore Block Deal Puts Gland Pharma Under Spotlight
Gland Pharma Ltd GLAND was one of the most closely watched pharmaceutical stocks on Friday after a large block transaction involving approximately **4.5% of the company's equity** changed hands.
Around **75 lakh shares** were traded in t…
Gland Pharma: Block Deal Buzz and Stock Performance
GLAND is back in focus after reports that its promoter, Fosun Pharma Industrial, is likely to sell a 5% equity stake through a block deal.
According to CNBC-TV18, citing sources, the proposed deal could be worth around ₹2,279.5 crore, wi…
Gland Pharma: Promoter Stake Sale in Block Deal
GLAND Gland Pharma is in focus today after significant block-deal activity involving the company’s shares. Around 1.22 crore shares changed hands across two large block deals, with the transactions valued at approximately ₹2,941 crore and…
4th Sep · SEBI Registration INH000022297
SEBI Registration INH000022297 · 4th Sep
Promoter stake sale puts Gland Pharma in focus
GLAND witnessed a block deal involving 75 lakh shares, equivalent to around 4.5% of the company, worth approximately ₹2,121 crore at an average price of about ₹2,828 per share. The transaction comes after reports that promoter Fosun Pharm…
3rd Sep · SEBI Registration INH000019886
SEBI Registration INH000019886 · 3rd Sep
Gland Pharma Limited Latest Updates with Discussion
GLAND Q1 FY27 Financial Performance & Core Injectables Growth
In August 2026, Gland Pharma announced its financial results for the first quarter ended June 30, 2026 (Q1 FY27). Consolidated revenue from operations grew 16% year-on-year to ₹…
Gland Pharma: USFDA Completes Inspection, No Observations
GLAND (Gland Pharma) announced the US FDA completed its inspection of the company's API facility in Visakhapatnam, conducted from August 24 to September 1, with no observations issued by the regulator.
Worth understanding what "no observ…
Gland Pharma: USFDA Inspection Ends With Zero Observations
Gland Pharma Ltd ( GLAND ) is in focus after the US Food and Drug Administration completed its inspection of the company's Visakhapatnam facilities with zero Form 483 observations.
The routine GMP inspection covered the company's VSEZ St…
Gland Pharma Shares Recover volatile USFDA Inspection
GLAND shares came under pressure on September 2, 2026, falling as much as 2.5% during the session, before recovering the entire decline and trading largely flat in afternoon trade. At around 3:18 PM IST, the stock was quoted at ₹2,873.90,…
A strong stock can outperform a weak market.
industry growth, earnings momentum, and investor confidence align together. Imagine the market is walking through a storm. The Nifty is under pressure, crude oil is rising, and sentiment is cautious. Yet, some companies continue climbing.…
Gland Pharma Gains Attention After Clean USFDA Inspection
GLAND Gland Pharma is in focus after the US Food and Drug Administration completed a routine GMP inspection at the company’s VSEZ Sterile Oncology formulations and API facilities in Visakhapatnam. The inspection concluded with zero Form 48…
📊 COMPANIES WITH STRONG RESULTS (NEHA GUPTA SEBI RA)
📊 COMPANIES WITH STRONG RESULTS
1️⃣ Power, Electrical & Energy
POLYCAB • SIEMENS • POWERINDIA • APARINDS • TDPOWERSYS • PREMIERENE • QPOWER
POLYCAB
2️⃣ Automobile & Auto Components
BAJAJ-AUTO • TVSMOTOR • CRAFTSMAN • SJS • ATHERENERG •…
📊 COMPANIES WITH STRONG RESULTS Strong results
📊 COMPANIES WITH STRONG RESULTS 1️⃣ Power, Electrical & Energy POLYCAB • SIEMENS • POWERINDIA • APARINDS • TDPOWERSYS • PREMIERENE • QPOWER 2️⃣ Automobile & Auto Components BAJAJ-AUTO • TVSMOTOR • CRAFTSMAN • SJS • ATHERENERG • GNA • MTA…
Stocks With Strong Future Guidance — Worth Tracking
• V-Marc
• RR Kabel
• Finolex
• HFCL HFCL
• E2E Networks
• MTAR Technologies
• Syrma SGS
• Netweb Technologies
• Sterlite Technologies
• Sansera Engineering
• Azad Engineering
• Omnitech Engineering
• Dynamatic Technologies
• Aequs
• Ross…
11th Aug · SEBI Registration INH000016755
SEBI Registration INH000016755 · 11th Aug
Gland Pharma shares rally 12%, lead Nifty Midcap gainers after strong Q1; Jefferies turns bullish
GLAND share price: Gland Pharma shares surged nearly 12 per cent on Tuesday, August 11, emerging as the biggest gainer on the Nifty Midcap 100 after the pharmaceutical company posted a strong performance for the June quarter.
Following t…
